<DOC>
	<DOCNO>NCT00759564</DOCNO>
	<brief_summary>This study evaluate effect renal dysfunction drug intravenous ( CP-70,429 ) oral form ( PF-03709270 ) .</brief_summary>
	<brief_title>A Study To Investigate The Pharmacokinetics , Safety And Tolerability Of An Intravenous And Oral Form Of A Compound In Subjects With Varying Degrees Of Renal Impairment And Normal Renal Function</brief_title>
	<detailed_description>To evaluate pharmacokinetics safety .</detailed_description>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Lactams</mesh_term>
	<criteria>Subjects must meet one follow renal function category : Normal renal function ( CLcr &gt; 80 mL/min ) . Mild renal impairment ( CLcr &gt; 50 &lt; 80 mL/min ) . Moderate renal impairment ( CLcr &gt; 30 &lt; 50 mL/min ) . Severe renal impairment ( CLcr &lt; 30 mL/min ) . Women pregnant nursing woman childbearing potential . History clinically significant allergy , include seasonal allergy , especially drug hypersensitivity include know allergy component study drug formulation , penicillin , carbapenems and/or cephalosporin antibiotic ( eg , amoxicillin , amoxicillin/clavulanate , ampicillin , cefadroxil , cephalexin , cefaclor cefixime ) . Subjects evidence history follow : normal renal function : clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurological allergic disease . renal impairment : clinically significant ( hepatic , cardiac pulmonary subject acute nephritic syndrome ) diseases ( except diabetes ) . Stable comorbid disease unlikely disease medication alter outcome study allow .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>